Johnson & Johnson (JNJ)
| Market Cap | 501.88B |
| Revenue (ttm) | 92.15B |
| Net Income (ttm) | 25.12B |
| Shares Out | 2.41B |
| EPS (ttm) | 10.35 |
| PE Ratio | 20.13 |
| Forward PE | 18.87 |
| Dividend | $5.20 (2.50%) |
| Ex-Dividend Date | Nov 25, 2025 |
| Volume | 7,499,852 |
| Open | 209.80 |
| Previous Close | 210.33 |
| Day's Range | 207.76 - 211.06 |
| 52-Week Range | 140.68 - 215.19 |
| Beta | 0.35 |
| Analysts | Buy |
| Price Target | 205.07 (-1.56%) |
| Earnings Date | Jan 21, 2026 |
About JNJ
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price target is $205.07, which is a decrease of -1.56% from the latest price.
News
Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma
- TRUFILL n-BCA is now indicated for embolization of the middle meningeal artery (MMA) for the treatment of symptomatic subacute and Chronic Subdural Hematoma (cSDH) as an adjunct to surgery. - Approv...
Johnson & Johnson: Valuation Premium Justified By Accelerating Growth And Mix Premiumization
Johnson & Johnson is rated a buy, with accelerating revenue and earnings growth driven by TREMFYA, CARVYKTI, and robust MedTech innovation. JNJ's portfolio reshaping (divesting Orthopaedics and focusi...
U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)
RYBREVANT FASPRO™, the first and only subcutaneous therapy for patients with EGFR-mutated NSCLC, reduces administration time from hours to minutes and significantly reduces administration-related reac...
Final Trade: JNJ, NVO, UBER, BMY
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, January 21st to review fourth-quarter results. J...
US FDA grants priority voucher to J&J's blood cancer treatment
The U.S. Food and Drug Administration said on Monday it has granted a national priority voucher to Johnson & Johnson's treatment for a type of blood cancer, bringing the total number of products recei...
California Jury Awards $40 Million in Landmark Talc Verdict Against Johnson & Johnson
LOS ANGELES--(BUSINESS WIRE)--A Los Angeles Superior Court jury on Friday delivered a $40 million verdict against Johnson & Johnson. The trial involved two women who developed ovarian cancer after dec...
Jury orders Johnson & Johnson to pay $40 million to two women in latest talc trial
A California jury on Friday awarded $40 million to two women who said Johnson & Johnson's baby powder was to blame for their ovarian cancer.
U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
Expanded indication for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) plus prednisone marks the first FDA-approved precision medicine combination treatment for patients with BRCA2-mut...
Johnson & Johnson: Reliable Cash Flows, Moderate Expectations
Johnson & Johnson has surged 14% since my last update, surpassing my $188 target, and now trades near $200. Top-line growth is accelerating, but revenue expansion remains below industry rates and is p...
GS Equity Income Fund: Q3 2025 Witnesses Fundamental Strength And Expansive Margin Opportunities
The US Equity Income Fund underperformed its benchmark, the Russell 1000 Value Index, net of fees during the third quarter. Enterprise software company, Oracle Corporation, was a top contributor to re...
5 defensive stocks traders are buying before the Fed rate-cut decision
With the Federal Reserve set to announce its final policy decision of 2025 on Wednesday, investors are rotating into defensive positions. More than the rate-cut possibility (which is around 90% as per...
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
TECVAYLI® and DARZALEX FASPRO® combination led to a statistically significant progression-free survival and overall survival advantage compared to standard treatment after three years of follow-up Com...
Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12th, 2026. Management will participate in a Fi...
Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression and treatment-free following a single infusion as early as second line Data suggest s...
Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
New data from Cohort 4 of the SunRISe-1 study show more than 95 percent of patients remained progression free at one year, with more than 92 percent not undergoing bladder removal Patients with this t...
Johnson & Johnson (JNJ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Johnson & Johnson (JNJ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
American Century Value Fund Q3 2025 Contributors/Detractors And Notable Trades
Shares of Teradyne advanced sharply as investors cheered the company's robust earnings and outlook for Teradyne's artificial intelligence compute testing business. We initiated a position in this cust...
16 Quality Stocks to Own for a Volatile Market
The S&P 500 has staged an impressive rebound, but is in for more swings.
Johnson & Johnson receives European Commission approval of IMAAVY® (nipocalimab), a new FcRn blocker offering sustained disease control in a broad population of people living with generalised myasthenia gravis (gMG)
Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive
Best Dividend Aristocrats For December 2025
The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed the SPDR S&P 500 ETF (SPY) year-to-date, but November shows a reversal. Several Dividend Aristocrats, including CAH, CAT, CHRW,...
Dogs Of The Dow Continue Outperforming Broader Market
Through the end of November, the year-to-date total return of the Dogs of the Dow equals 20.96%, outpacing the Dow Jones Industrial Average return of 13.86% and outpacing the broader S&P 500 Index ret...
Wasatch Global Value Fund Q3 2025 Performance Review
The Wasatch Global Value Fund - Investor Class gained 6.36% in the third quarter of 2025, outperforming the MSCI All Country World Value Index, which added 6.13%. Leading contributors to the Fund's pe...
JNJ Stock vs. PFE Stock: Which Pharmaceutical Giant Is A Better Buy?
The pharmaceutical powerhouse Johnson & Johnson (NYSE: JNJ) has significantly outperformed its competitor Pfizer (NYSE: PFE) this year. JNJ's stock has risen by almost 45%, whereas PFE has declined by...
